Iovance Biotherapeutics (IOVA) Assets (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Assets of $925.7 million for Q1 2026, down 4.25% year-over-year from $966.7 million in Q1 2025, and up 1.37% quarter-over-quarter from $913.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Assets (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Assets for 17 consecutive years, with $925.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 4.25% year-over-year to $925.7 million; the TTM figure through Mar 2026 stood at $925.7 million (down 4.25% YoY), while the FY2025 annual figure was $913.2 million, changed 0.3% from the prior year.
- Assets rose to $925.7 million in Q1 2026 per IOVA's latest filing, from $913.2 million in the prior quarter.
- Across five years, Assets topped out at $966.7 million in Q1 2025 and bottomed at $545.9 million in Q3 2022.
- Historically, Assets has averaged $809.0 million across 5 years, with a median of $852.3 million in 2023.
- Annual changes were most pronounced in 2022 — Assets slumped 34.13% — and 2023, when it soared 56.12%.
- Iovance Biotherapeutics' Assets stood at $664.0 million in 2022, then grew by 17.53% to $780.4 million in 2023, then advanced by 16.67% to $910.4 million in 2024, then grew by 0.3% to $913.2 million in 2025, then increased by 1.37% to $925.7 million in 2026.
- Business Quant data shows IOVA's Assets at $925.7 million in Q1 2026, $913.2 million in Q4 2025, and $904.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 915.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 915.53 Mn |
| Mar 31, 2026 | 925.67 Mn |
| Dec 31, 2025 | 913.17 Mn |
| Sep 30, 2025 | 904.95 Mn |
| Jun 30, 2025 | 907.44 Mn |
| Mar 31, 2025 | 966.74 Mn |
| Dec 31, 2024 | 910.43 Mn |
| Mar 31, 2024 | 869.83 Mn |
| Dec 31, 2023 | 780.35 Mn |
| Sep 30, 2023 | 852.32 Mn |
| Jun 30, 2023 | 757.29 Mn |
| Mar 31, 2023 | 824.77 Mn |
| Dec 31, 2022 | 663.98 Mn |
| Sep 30, 2022 | 545.92 Mn |
| Jun 30, 2022 | 610.88 Mn |
| Mar 31, 2022 | 701.25 Mn |
| Dec 31, 2021 | 777.33 Mn |
| Sep 30, 2021 | 828.83 Mn |
| Jun 30, 2021 | 852.79 Mn |
| Mar 31, 2021 | 750.57 Mn |